Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Annunziata Website

Christina M. Annunziata, M.D., Ph.D.

Selected Publications

1)  Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM.
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Cancer Cell. 12: 115-30, 2007.
[Journal]
2)  Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC.
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.
Cancer. 116: 3276-84, 2010.
[Journal]
3)  Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM.
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.
Cancer Res. 70: 4005-14, 2010.
[Journal]
4)  Hsu S, Kim M, Hernandez L, Grajales V, Noonan A, Anver M, Davidson B, Annunziata CM.
IKK-e coordinates invasion and metastasis of ovarian cancer.
Cancer Res. 72: 5494-504, 2012.
[Journal]
5)  Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Ohler ZW, Difilippantonio S.
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
PLoS ONE. 9: e95649, 2014.
[Journal]
6)  Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses.
J. Natl. Cancer Inst. 106, 2014.
[Journal]
7)  House CD, Hernandez L, Annunziata CM.
Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer.
Front Oncol. 4: 26, 2014.
[Journal]
8)  Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC.
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.
Mol Clin Oncol. 1: 565-569, 2013.
[Journal]
9)  Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
Br. J. Cancer. 109: 1072-8, 2013.
[Journal]
10)  Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC.
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.
Cancer. 119: 1357-64, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/16/2014.